375 related articles for article (PubMed ID: 24169729)
21. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation.
Blaes AH; Cao Q; Wagner JE; Young JA; Weisdorf DJ; Brunstein CG
Biol Blood Marrow Transplant; 2010 Feb; 16(2):287-91. PubMed ID: 19835968
[TBL] [Abstract][Full Text] [Related]
22. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
Styczynski J; Einsele H; Gil L; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
[TBL] [Abstract][Full Text] [Related]
23. Anti-CD20 monoclonal antibody (Rituximab) and Cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement.
Hänel M; Fiedler F; Thorns C
Onkologie; 2001 Oct; 24(5):491-4. PubMed ID: 11694778
[TBL] [Abstract][Full Text] [Related]
24. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
Patel C; Pasciolla M; Abramova R; Salerno D; Gomez-Arteaga A; Shore TB; Orfali N; Mayer S; Hsu J; Phillips AA; Chaekal OK; Satlin MJ; Soave R; Kodiyanplakkal RPL; Drelick A; Plate M; Besien KV
Transplant Cell Ther; 2023 Feb; 29(2):132.e1-132.e5. PubMed ID: 36334653
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab.
Garceau P; Couture C; Cantin B; Bernier V; Sénéchal M
J Heart Lung Transplant; 2008 Aug; 27(8):928-31. PubMed ID: 18656811
[TBL] [Abstract][Full Text] [Related]
26. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation.
Zilz ND; Olson LJ; McGregor CG
J Heart Lung Transplant; 2001 Jul; 20(7):770-2. PubMed ID: 11448808
[TBL] [Abstract][Full Text] [Related]
27. Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder.
Czyzewski K; Styczynski J; Krenska A; Debski R; Zajac-Spychala O; Wachowiak J; Wysocki M
Leuk Lymphoma; 2013 Mar; 54(3):503-6. PubMed ID: 22873830
[TBL] [Abstract][Full Text] [Related]
28. Epstein barr virus hemophagocytic lymphohistiocytosis related to rituximab use and immunopathogenetic insights.
Papageorgiou SG; Tsiodras S; Siakallis G; Bazani E; Spathis A; Poulakou G; Korkolopoulou P; Panayiotides I; Pappa V
Pathol Res Pract; 2016 Dec; 212(12):1194-1198. PubMed ID: 28340951
[TBL] [Abstract][Full Text] [Related]
29. Treatment of Epstein-Barr virus--associated lymphoproliferative disorder (EBV-PTLD) and pure red cell aplasia (PRCA) with Rituximab following unrelated cord blood transplantation: a case report and literature review.
Zhu K; Chen J; Chen S
Hematology; 2005 Oct; 10(5):365-70. PubMed ID: 16273722
[TBL] [Abstract][Full Text] [Related]
30. Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant.
Bonney DK; Htwe EE; Turner A; Kelsey A; Shabani A; Hughes S; Hughes I; Wynn RF
Pediatr Blood Cancer; 2012 Mar; 58(3):459-61. PubMed ID: 21584931
[TBL] [Abstract][Full Text] [Related]
31. Ofatumumab for Post-Transplant Lymphoproliferative Disorder.
Seshadri M; Crane GM; Gergis U
Hematol Oncol Stem Cell Ther; 2022 Mar; 15(1):68-73. PubMed ID: 32413419
[TBL] [Abstract][Full Text] [Related]
32. Epstein-Barr virus-associated post-transplant lymphoproliferative disorder presenting with skin involvement after CD34-selected autologous peripheral blood stem cell transplantation.
Takahashi S; Watanabe D; Miura K; Ozawa H; Tamada Y; Hara K; Matsumoto Y
Eur J Dermatol; 2007; 17(3):242-4. PubMed ID: 17478388
[TBL] [Abstract][Full Text] [Related]
33. [Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation].
Liu QF; Fan ZP; Luo XD; Zhang Y; Sun J
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(44):3123-6. PubMed ID: 19159594
[TBL] [Abstract][Full Text] [Related]
34. Unmanipulated donor lymphocytes for EBV-related PTLD after T-cell depleted HLA-haploidentical transplantation.
De Pasquale MD; Mastronuzzi A; De Vito R; Cometa A; Inserra A; Russo C; De Ioris MA; Locatelli F
Pediatrics; 2012 Jan; 129(1):e189-94. PubMed ID: 22144701
[TBL] [Abstract][Full Text] [Related]
35. Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy.
Raberahona M; Wackenheim C; Germi R; Carré M; Bulabois CE; Thiébaut A; Lupo J; Semenova T; Cahn JY; Morand P; Epaulard O
Transpl Infect Dis; 2016 Dec; 18(6):889-895. PubMed ID: 27696681
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus-positive mucocutaneous ulcer arising in a post-hematopoietic cell transplant patient followed by polymorphic posttransplant lymphoproliferative disorder and cytomegalovirus colitis.
Satou A; Kohno A; Fukuyama R; Elsayed AA; Nakamura S
Hum Pathol; 2017 Jan; 59():147-151. PubMed ID: 27569297
[TBL] [Abstract][Full Text] [Related]
37. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
Ganne V; Siddiqi N; Kamaplath B; Chang CC; Cohen EP; Bresnahan BA; Hariharan S
Clin Transplant; 2003 Oct; 17(5):417-22. PubMed ID: 14703923
[TBL] [Abstract][Full Text] [Related]
38. Rituximab-containing immuno-chemotherapy regimens are effective for the elimination of EBV for EBV-HLH with only and mainly B lymphocytes of EBV infection.
Meng GQ; Wang JS; Wang YN; Wei N; Wang Z
Int Immunopharmacol; 2021 Jul; 96():107606. PubMed ID: 33826999
[TBL] [Abstract][Full Text] [Related]
39. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
[TBL] [Abstract][Full Text] [Related]
40. Primary Cutaneous Polymorphic EBV-Associated Posttransplant Lymphoproliferative Disorder After a Renal Transplant and Review of the Literature.
Ferguson NN; Thomas CP; Hohl RJ; Syrbu SI; Stone MS; Wanat KA
Am J Dermatopathol; 2015 Oct; 37(10):790-4. PubMed ID: 25747810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]